Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording

Giovanna Calandra-Buonaura, Pietro Guaraldi, Andrea Doria, Stefano Zanigni, Stefania Nassetti, Valentina Favoni, Sabina Cevoli, Federica Provini, Pietro Cortelli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sleep disturbances represent important predictors of poor quality of life (QoL) in Parkinson's disease (PD). This open-label pilot study aimed to objectively assess, by means of actigraphic recording, effect of rotigotine on sleep in PD patients with self-reported sleep complaints. 15 PD patients underwent one-week actigraphic recording before (T0) and during (T1) rotigotine treatment, which was titrated to the dose subjectively improving motor symptoms (4-8 mg/24 h). Sleep disturbances, daytime sleepiness, cognitive performance, QoL, and depression were also evaluated with questionnaires. Actigraphic recordings showed a significant reduction in nocturnal motor activity and mean duration of wake episodes after sleep onset during rotigotine treatment compared to baseline. In 10 patients presenting objective evidence of poor sleep quality at T0 (sleep efficiency ≤ 85%), rotigotine also significantly improved other sleep parameters and further reduced nocturnal motor activity and mean duration of wake episodes. A significant decrease in number and duration of daytime sleep episodes was also observed at T1. Finally we confirmed that rotigotine significantly improves perceived sleep quality and QoL. Our study showed for the first time that rotigotine is associated with an objective improvement of nocturnal and diurnal sleep disturbances in PD patients with self-reported sleep complaints. This study is registered with AIFA-observational study registry number 12021.

Original languageEnglish
Article number3724148
Pages (from-to)1-5
JournalParkinson's Disease
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Parkinson Disease
Sleep
Quality of Life
N 0437
Motor Activity
Observational Studies
Registries
Depression

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Rotigotine Objectively Improves Sleep in Parkinson's Disease : An Open-Label Pilot Study with Actigraphic Recording. / Calandra-Buonaura, Giovanna; Guaraldi, Pietro; Doria, Andrea; Zanigni, Stefano; Nassetti, Stefania; Favoni, Valentina; Cevoli, Sabina; Provini, Federica; Cortelli, Pietro.

In: Parkinson's Disease, Vol. 2016, 3724148, 2016, p. 1-5.

Research output: Contribution to journalArticle

@article{efbbe321588a4391aa99749ef2d5d422,
title = "Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording",
abstract = "Sleep disturbances represent important predictors of poor quality of life (QoL) in Parkinson's disease (PD). This open-label pilot study aimed to objectively assess, by means of actigraphic recording, effect of rotigotine on sleep in PD patients with self-reported sleep complaints. 15 PD patients underwent one-week actigraphic recording before (T0) and during (T1) rotigotine treatment, which was titrated to the dose subjectively improving motor symptoms (4-8 mg/24 h). Sleep disturbances, daytime sleepiness, cognitive performance, QoL, and depression were also evaluated with questionnaires. Actigraphic recordings showed a significant reduction in nocturnal motor activity and mean duration of wake episodes after sleep onset during rotigotine treatment compared to baseline. In 10 patients presenting objective evidence of poor sleep quality at T0 (sleep efficiency ≤ 85{\%}), rotigotine also significantly improved other sleep parameters and further reduced nocturnal motor activity and mean duration of wake episodes. A significant decrease in number and duration of daytime sleep episodes was also observed at T1. Finally we confirmed that rotigotine significantly improves perceived sleep quality and QoL. Our study showed for the first time that rotigotine is associated with an objective improvement of nocturnal and diurnal sleep disturbances in PD patients with self-reported sleep complaints. This study is registered with AIFA-observational study registry number 12021.",
author = "Giovanna Calandra-Buonaura and Pietro Guaraldi and Andrea Doria and Stefano Zanigni and Stefania Nassetti and Valentina Favoni and Sabina Cevoli and Federica Provini and Pietro Cortelli",
note = "Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Universit{\`a} di Bologna (Calandra Buonaura Giovanna, Provini Federica, Cortelli Pietro)",
year = "2016",
doi = "10.1155/2016/3724148",
language = "English",
volume = "2016",
pages = "1--5",
journal = "Parkinson's Disease",
issn = "2090-8083",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Rotigotine Objectively Improves Sleep in Parkinson's Disease

T2 - An Open-Label Pilot Study with Actigraphic Recording

AU - Calandra-Buonaura, Giovanna

AU - Guaraldi, Pietro

AU - Doria, Andrea

AU - Zanigni, Stefano

AU - Nassetti, Stefania

AU - Favoni, Valentina

AU - Cevoli, Sabina

AU - Provini, Federica

AU - Cortelli, Pietro

N1 - Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Università di Bologna (Calandra Buonaura Giovanna, Provini Federica, Cortelli Pietro)

PY - 2016

Y1 - 2016

N2 - Sleep disturbances represent important predictors of poor quality of life (QoL) in Parkinson's disease (PD). This open-label pilot study aimed to objectively assess, by means of actigraphic recording, effect of rotigotine on sleep in PD patients with self-reported sleep complaints. 15 PD patients underwent one-week actigraphic recording before (T0) and during (T1) rotigotine treatment, which was titrated to the dose subjectively improving motor symptoms (4-8 mg/24 h). Sleep disturbances, daytime sleepiness, cognitive performance, QoL, and depression were also evaluated with questionnaires. Actigraphic recordings showed a significant reduction in nocturnal motor activity and mean duration of wake episodes after sleep onset during rotigotine treatment compared to baseline. In 10 patients presenting objective evidence of poor sleep quality at T0 (sleep efficiency ≤ 85%), rotigotine also significantly improved other sleep parameters and further reduced nocturnal motor activity and mean duration of wake episodes. A significant decrease in number and duration of daytime sleep episodes was also observed at T1. Finally we confirmed that rotigotine significantly improves perceived sleep quality and QoL. Our study showed for the first time that rotigotine is associated with an objective improvement of nocturnal and diurnal sleep disturbances in PD patients with self-reported sleep complaints. This study is registered with AIFA-observational study registry number 12021.

AB - Sleep disturbances represent important predictors of poor quality of life (QoL) in Parkinson's disease (PD). This open-label pilot study aimed to objectively assess, by means of actigraphic recording, effect of rotigotine on sleep in PD patients with self-reported sleep complaints. 15 PD patients underwent one-week actigraphic recording before (T0) and during (T1) rotigotine treatment, which was titrated to the dose subjectively improving motor symptoms (4-8 mg/24 h). Sleep disturbances, daytime sleepiness, cognitive performance, QoL, and depression were also evaluated with questionnaires. Actigraphic recordings showed a significant reduction in nocturnal motor activity and mean duration of wake episodes after sleep onset during rotigotine treatment compared to baseline. In 10 patients presenting objective evidence of poor sleep quality at T0 (sleep efficiency ≤ 85%), rotigotine also significantly improved other sleep parameters and further reduced nocturnal motor activity and mean duration of wake episodes. A significant decrease in number and duration of daytime sleep episodes was also observed at T1. Finally we confirmed that rotigotine significantly improves perceived sleep quality and QoL. Our study showed for the first time that rotigotine is associated with an objective improvement of nocturnal and diurnal sleep disturbances in PD patients with self-reported sleep complaints. This study is registered with AIFA-observational study registry number 12021.

UR - http://www.scopus.com/inward/record.url?scp=84960145349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960145349&partnerID=8YFLogxK

U2 - 10.1155/2016/3724148

DO - 10.1155/2016/3724148

M3 - Article

C2 - PMID: 26981312

AN - SCOPUS:84960145349

VL - 2016

SP - 1

EP - 5

JO - Parkinson's Disease

JF - Parkinson's Disease

SN - 2090-8083

M1 - 3724148

ER -